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Enterovirus (EV) 71 has emerged as a primary cause 
of severe neurologic enterovirus infection in the after-
math of the global polio eradication effort. Eleven sub-
genotypes of EV71 exist, the C4 subgenotype being 
associated with large outbreaks in Asia with high mor-
tality rates. This subgenotype has rarely been reported 
in Europe. In the period between 1 January 2009 and 
31 December 2013 a total of 1,447 EV positive samples 
from 1,143 individuals were sent to the Statens Serum 
Institute (SSI), and 938 samples from 913 patients 
were genotyped at the Danish National World Health 
Organization Reference laboratory for Poliovirus at 
SSI. Echovirus 6 (E06) (n=141 patients), echovirus 30 
(E30) (n=114), coxsackievirus A6 (CA06) (n=96) and 
EV71 (n=63) were the most prevalent genotypes. We 
observed a shift in circulating EV71 subgenotypes dur-
ing the study period, with subgenotype C4 dominat-
ing in 2012. A total of 34 EV71 patients were found to 
be infected with strains of the C4 subgenotype, and 
phylogenetic analysis revealed that they belonged to 
the C4a lineage. In our study, the proportions of cases 
with cerebral and/or sepsis-like symptoms were simi-
lar in those affected by C4a (19/34) and those with C1 
and C2 (15/35). The majority (n=30) of the 34 EV71 C4 
cases were children ≤5 years of age, and males (n=22) 
were over-represented. Continued EV surveillance is 
required to monitor the spread of EV71 C4 in Denmark 
and the rest of Europe.  
Introduction
Human enteroviruses (EV) are small, single-stranded 
RNA-viruses from the Enterovirus genus of the 
Picornaviridae family. They can cause a range of clini-
cal manifestations from mild mucocutaneous and/
or gastrointestinal symptoms, to visceral and severe 
neurologic diseases with involvement of central nerv-
ous system (CNS). Polioviruses used to be the most 
important EV due to widespread outbreaks of paralytic 
disease. A rather successful global effort to eradicate 
polio has now made EV71 the primary cause of severe 
neurotropic EV-associated infectious diseases [1]. 
EV71 variants have been classified into three geno-
groups (GgA, GgB, and GgC), and the latter two are 
further subdivided into subgenotypes B1 to B5, and 
C1 to C5. Currently genogroups B and C are co-circu-
lating worldwide. Subgenotype C1 is predominating in 
Europe, but it can also be found in Australia, Malaysia 
and Singapore. The C4 subgenotype has predomi-
nantly been identified in large outbreaks of hand, foot 
and mouth disease (HFMD) in Asia, and in particu-
lar mainland China, where severe cases and a rather 
high mortality rate have been reported [2-4]. In 2004 
the C4 subgenotype was detected for the first time in 
Europe, and has to date only been reported in a total 
of nine cases in Austria, Croatia, and Hungary, respec-
tively [2-4]. In February 2012, the first EV71 C4 case 
was detected in Denmark in a Serbian infant admit-
ted to the paediatric ward at Hospital A with fever and 
CNS symptoms. In the following months more EV71 C4 
cases were detected in the same geographical area as 
the hospital. The Virology Surveillance and Research 
Section (VOF) at the Department of Microbiological 
Diagnostics and Virology, Statens Serum Institut (SSI) 
serves as the National World Health Organization 
(WHO) Reference Laboratory for Poliovirus in Denmark. 
The Danish EV surveillance is implemented to monitor 
poliomyelitis as part of the polyomyelitis elimination 
efforts in Denmark. We took advantage of the well-
functioning EV-surveillance system to characterise the 
emergence of EV71 C4 strains in Denmark.
Methods
Enterovirus surveillance system
The national EV surveillance system in Denmark is con-
ducted in a joint effort by the National WHO Poliovirus 
Reference Laboratory at VOF, SSI and the Infectious 
Disease Epidemiology Department (IDED) at SSI. The 
system is voluntary and all types of EV positive sam-
ple material may be submitted for characterisation. 
However, as part of the global poliovirus elimination 
programme, in case a patient is diagnosed with EV 
in the cerebrospinal fluid (CSF), it is highly requested 
that CSF and stool are forwarded to the Danish WHO 
Reference Laboratory for Poliovirus for virus charac-
terisation including culture and viral protein (VP)1/
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VP2 sequence-based typing. Samples for diagnostic 
testing may also be sent directly to SSI from general 
practitioners and hospitals. Once weekly, VOF, SSI 
reports the new EV positive cases to the WHO Regional 
Office for Europe (EURO) in Copenhagen, as well as to 
the IDED. To ensure that relevant clinical information 
is archived in the national EV surveillance database, 
the IDED sends a letter with a standardised question-
naire regarding information on the clinical symptoms 
(including information on acute flaccid paralysis) and 
a reminder to send stool for virus characterisation 
directly to the doctors/departments in charge of the 
EV-positive patients. Completed questionnaires are 
returned and data entered in the database by the IDED, 
SSI. To ensure completeness of clinical data informa-
tion for this paper, we have contacted relevant hospital 
departments and asked for relevant information on all 
EV71 cases where clinical information was missing.
Enterovirus characterisation
Isolates from all severe (i.e. with meningitis, encepha-
litis and sepsis-like illness) EV positive cases are rou-
tinely typed centrally at the VOF at SSI by sequencing 
part of the VP2 gene from the polymerase chain reac-
tion (PCR) product obtained directly from the diagnos-
tic sample, as VP2 sequencing has been demonstrated 
to be more sensitive than VP1 sequencing [5]. VP1 
sequencing is performed in cases where VP2 typing 
is unsuccessful, or for specific typing analyses. Non-
typeable virus isolates are cultivated in two cell-lines 
according to WHO guidelines [6] and then character-
ised by VP1 and VP2 sequencing. For this study, all 
samples that were positive for EV71 in diagnostic PCR 
were tested by VP1/VP2 sequencing. VP1 typing and 
sequencing was applied to comply with international 
EV characterisation standards. The sample materials 
for EV71 C4 positive patients are further described 
(results section).
RNA was extracted from 200 µl of CSF using the 
QiaCube with the Qia AMP DNA Blood Mini Kit (QIAGEN 
Nordic, Copenhagen, Denmark), or from 200 µl of other 
sample material (such as faeces, swabs, biopsies) 
using the MagNa pure LC robot with the total nucleic 
acids kit (Roche Diagnostics A/S, Hvidovre, Denmark). 
Diagnostic PCR for EV was conducted as described 
previously [7]. 5 µl of the extraction was used as tem-
plate for PCR amplifying part of the VP1 and VP2 gene, 
respectively in semi-nested PCR [5]. cDNA synthesis 
and first round PCR was carried out using a OneStep 
reverse transcription (RT)-PCR kit (QIAGEN Nordic, 
Copenhagen, Denmark), and second round amplifi-
cation was carried out, producing a VP1 amplicon of 
350 to 400 basepairs and a VP2 PCR amplicon of 368 
basepairs.
Prior to sequencing, PCR products were purified 
using exo-SAP IT (GE Healthcare, Buckinghamshire, 
UK). Purified PCR products were sequenced in both 
directions. Phylogenetic analysis based on the VP1 
Figure 1 
Distribution of enterovirus genotypes, Denmark, 2009–2013 (n=938)a
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Genotypes for which 10 or more viruses were detected are shown. Genotypes for which fewer than 10 viruses were detected are grouped 
together according to which enterovirus (EV) species they belong to, i.e. EVA, EVB, EVC, and EVD. The viruses which are grouped according 
to species are shown immediately after the last genotype of that species in the chart.
a  A total of 938 strains were characterised from 913 individuals. Of the 938 strains, 25 represent either co-infections with two different 
genotypes, or a subsequent infection with a different genotype.   
3www.eurosurveillance.org
sequences was carried out by maximum likelihood and 
the Kimura 2-parameter model with discrete gamma 
distribution and invariable sites, and 1,000 bootstrap 
replications using the Molecular Evolutionary Genetics 
Analysis (MEGA)5 software package [8]. VP1 sequence 
data from 23 of the 34 EV71 subgenotype C4 samples 
were of sufficient quality and length to be included in 
the phylogenetic analysis (sequence length 178–305 
nucleotides). All sequences from this study have been 
submitted to GenBank. Two subgenotype C1 strains 
and 11 subgenotype C2 strains were also included, as 
were all publically available (GenBank) European EV71 
C4 sequences. The analysis was supplemented with 
reference sequences obtained from GenBank repre-
senting EV71 subgenotypes A, B1 to B5, and C1 to C5 
(including C4a and C4b).
Results
In the period from 1 January 2009 to 31 December, 2013 
a total of 7,879 samples from 5,611 individuals were 
received at the Department of Microbiology Diagnostic 
and Virology at SSI for EV diagnostics. Of these, 984 
(12%) samples from 779 (14%) different individuals 
were positive for EV. In the same period 544 EV posi-
tive samples from 427 individuals were received for our 
national surveillance, thus totalling 1,447 positive sam-
ples from 1,143 individuals. 938 EV samples from 913 
individuals were successfully genotyped. In 25 individ-
uals more than one EV genotype was detected. A total 
of 41 different genotypes were identified, the most 
prevalent being E06 (n=141/913, 15%), E30 (n=114/913, 
12%), CA06 (n=96/913, 11%), and EV71 (n=63/913, 7%) 
(Figure 1).
EV71 was detected throughout the entire period, how-
ever there was a marked shift in the subgenotype, from 
C1 (n=3) and C2 (n=23), being found mainly between 
2009 and 2011 with additionally C2 in 2012 (n=1) and 
2013 (n=2), to subgenotype C4 being found primarily 
in 2012 (n=30) but also in 2013 (n=4) (Figure 2). The 34 
EV71 C4 infected individuals were unevenly distributed 
with regard to sex, as 22 of the 34 cases were males. 
With regards to age, the majority of infected individu-
als were young children, with 30 of the 34 C4 cases ≤5 
years-old, and 16 <1 year-old.
With regard to the severity of symptoms, patients 
infected with the C4 subgenotype showed comparable 
symptoms to patients infected with subgenotypes C1 
and/or C2 (Table 1 and 2). Nineteen of the 34 C4 patients 
had cerebral or sepsis-like symptoms. Additional 
symptoms among the EV71 C4 infected cases were 
gastroenteritis (n=7), and HFMD (n=4). EV71 C4 was 
detected primarily from stool samples (n=19/34, Table 
1). Except for the single clustering of EV71 C4 cases in 
Funen during the months of July to December of 2012 
(n=12), most single cases appear sporadically through-
out the study period and from all five major geographi-
cal regions of Denmark (Table 1). Of the 12 clustered 
cases from Funen, 10 were admitted to the central hos-
pital and one case was referred to this hospital from a 
nearby provincial hospital. The age range was 0 to 40 
years (median: 2 years), with an uneven sex distribu-
tion of nine males, and three females.
The phylogenetic analysis revealed one major C4 lin-
eage, containing all of the C4 strains reported in this 
study (Figure 3). These were determined to belong 
to the C4a lineage from Asia. Previously reported C4 
strains from Europe belong to the C4b lineage [2-4].
Discussion
This study reports the finding of a new EV71 C4a sub-
genotype, detected in Denmark for the first time in the 
spring of 2012. As of December 2013 a further 33 EV71 
C4 cases have been detected, the majority in infants 
with moderate to severe symptoms. EV71 C4 cases from 
Austria and Hungary were also found to be associated 
with severe symptoms such as meningitis and acute 
flaccid paralysis [2,3]. In Denmark, study material is 
based on cases referred for either diagnostic purposes, 
or submitted to the National WHO Polio Reference 
Laboratory at SSI, as part of the national EV surveil-
lance. As a consequence, the detection of mild and/
or asymptomatic cases of EV71 infection in the Danish 
population is not complete, and we can therefore not 
conclude that EV71 C4 is always associated with severe 
symptomatology. Only 6/63 EV71 cases were associ-
ated with HFMD. There is no specific surveillance for 
HFMD in Denmark, so the actual level of mild cases of 
EV71 in circulation may be underestimated.
The EV71 C4 strains identified in Denmark shared a 
surprisingly high sequence similarity with an EV71 C4a 
epidemic strain from China, 2008 (EU913466, Figure 
3) [9-11]. So far, the relatively severe presentation, 
although with no fatalities, of 19 of the 34 EV71 C4 
cases, with a temporal-spatial clustering of nine of the 
meningitis/encephalitis cases in Funen during the sec-
ond half of 2012, suggests that the Danish emerging C4 
strain has the same potential for a high transmission 
Figure 2 
Distribution of enterovirus 71 subgenotypes C1, C2, and 
C4, Denmark, 2009–2013 (n=63)
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rate and high pathogenicity as described previously for 
Asian EV71 C strains, including EV71 C4 [9-13].
Other EV71 C subgenotypes, namely C1 and C2, have 
previously been identified as occurring sporadically in 
Denmark throughout a four year study period (2005 to 
2008), implying simultaneous circulation of these line-
ages without genetic selection of either strain based 
on VP2 sequences [14]. However, only one EV71 C2 case 
was identified during 2012 and two in 2013, suggest-
ing that the introduction of C4 within the population of 
Denmark might have a suppressive impact on the cir-
culation of other EV71 C subgenotypes. Furthermore, 
the number of EV71 positive samples in 2012 (n=31) is 
in itself notable, as a total of only 29 EV71 cases were 
identified throughout the previous four-year study 
period [11]. It will be interesting to follow the emer-
gence of C4, and see whether it will follow the typical 
trend of the other EV71 subgenotypes with only limited 
evolutionary change within its two lineages (C4a and 
C4b) over time, or whether this subgenotype will con-
tinue to dominate the future EV seasons and give rise to 
outbreaks of severe disease in Europe, as the C4s are 
known for in parts of Asia. The increasing number of 
EV71 C4 identified during the 2009 to 2013 surveillance 
period, and the initial clustering of 11 cases within one 
Table 1
Characteristics of enterovirus 71 C4 infected patients, Denmark, 2009–2013 (n=34 patients)
Patient 
number Age in Years Sex Date of sampling
Geographical
region
Primary
symptoms Sample material
1 0 M 11-02-2012 Funen Meningitis Faecal swab
2 0 M 22-05-2012 Jutland Meningitis Stool
3 2 M 06-07-2012 Funen Gastroenteritis Swab
4 4 M 09-07-2012 Funen Meningitis Faecal swab
5 3 F 23-07-2012 Jutland Encephalitis Stool
6 0 F 01-08-2012 Jutland Gastroenteritis Stool
7 0 F 22-08-2012 Funen Sepsis-like syndrome Stool
8 40 M 30-08-2012 Funen Meningitis CSF
9 2 M 04-09-2012 Funen Meningitis Stool
10 0 F 11-09-2012 Zealand Fever Stool
11 1 M 13-09-2012 Zealand Unknown Fluid
12 6 M 27-09-2012 Jutland HFMD Swab
13 29 M 11-10-2012 Jutland Respiratory symptoms Swab
14 0 F 14-10-2012 Jutland Gastroenteritis Stool
15 0 M 17-10-2012 Funen Encephalitis Swab
16 3 M 26-10-2012 Funen Meningitis Swab
17 0 M 26-10-2012 Jutland Meningitis Stool
18 1 M 30-10-2012 Funen Encephalitis Swab
19 0 M 04-11-2012 Funen Gastroenteritis Stool
20 0 M 05-11-2012 Funen Meningitis Stool
21 0 M 07-11-2012 Zealand Sepsis-like syndrome Stool
22 0 F 08-11-2012 Zealand Sepsis-like syndrome Stool
23 0 M 09-11-2012 Funen Meningitis Stool
24 4 M 16-11-2012 Jutland Meningitis Stool
25 1 F 25-11-2012 Jutland Fever Stool
26 1 F 28-11-2012 Jutland Gastroenteritis Stool
27 33 F 06-12-2012 Zealand HFMD Vesicle fluid
28 2 M 07-12-2012 Zealand HFMD Swab
29 3 M 11-12-2012 Jutland Gastroenteritis Stool
30 4 F 18-12-2012 Funen Meningitis Swab
31 0 M 08-01-2013 Jutland Gastroenteritis Stool
32 2 F 16-07-2013 Jutland Meningitis+HFMD Faecal swab
33 0 M 22-08-2013 Zealand Meningitis CSF
34 0 F 03-10-2013 Jutland Fever Stool
CSF: cerebrospinal fluid; HFMD: hand foot and mouth disease; M: male; F: female.
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hospital during the second half of 2012, suggest that 
this subgenotype initially gave rise to a smaller local-
ised outbreak and is potentially now establishing itself 
in this northern European population. In the recent ‘per-
spective’ from the Global Disease Detection Operations 
Center at the United States Centers for Disease Control 
and Prevention (CDC), EV71 was considered to be one 
of the top-five global infectious disease threats to 
watch, due to its propensity to cause large outbreaks 
and severe, life threatening, neurologic disease [15].
In conclusion, the circulation of EV71 subgenotype C4a 
in Denmark has been established. Based on obser-
vations using a wide range of different samples from 
patients with a broad range of EV symptoms, this 
subgenotype was found to coincide with severe dis-
ease, as were the other EV71 subgenotypes C1 and 
C2, detected in Denmark during the study period. EV 
surveillance of high quality and high sample volume is 
needed to closely monitor the continued emergence of 
EV71 C4 in the European population over the coming 
years to establish the pathogenicity and virulence of 
this subgenotype. A broader emergence of EV71 within 
Europe might potentially widen the focus of the current 
development of EV71 vaccines for targeted use in Asia, 
to a potential future benefit in Europe as well [16,17].
Table 2
Main clinical presentation of enterovirus (EV)71 C4 and 
EV71 C1 and EV71 C2 patients, Denmark, 2009–2013 
(n=63)
Symptom C4 patients C2+C1 patients
Meningitis 13 12
Gastroenteritis 7 7
HFMD 4 2
Encephalitis 3 2
Sepsis-like syndrome 3 1
Respiratory symptoms 1 1
Fever 3 6
Myoclonus 0 1
Unknown 1 1
Total number of patients 34a 29a
HFMD: hand foot and mouth disease.
a  Some patients presented more than one symptom so the total 
numbers of patients are not equal to the sum of the numbers in 
the respective columns.
Figure 3 
Phylogenetic analysis of viral protein 1 sequences from 
Danish enterovirus 71 strains, Denmark, 2009–2013 
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Danish enterovirus (EV)71 strains are represented with a black 
square. The sequence identifiers for the sequences obtained in 
this study are made up of a two figure prefix to denote the year 
of sample collection, followed by our internal sample number. 
Subgenotype C reference sequences were downloaded from 
GenBank (EV71 C1 accession number: DQ341360; EV71 C2: 
AF136379; EV71 C3: DQ341355; EV71 C4a: EU913466; EV71 C4b: 
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